Pathways to Cardiovascular Therapeutics
Pathways to Cardiovascular Therapeutics
批准号:
8986055
负责人:
Joshua M Hare
金额:
$3.0万
依托单位国家:
美国
项目类别:
财政年份:
2015
资助国家:
美国
项目状态:
已结题
起止时间:
2015-07-01 至 2016-06-30
关键词:
American Heart AssociationAnniversaryAreaAwardBackBiologyBudgetsCardiacCardiac developmentCardiologyCardiovascular systemCell TherapyCellsCollaborationsCommunitiesDisabled PersonsDiseaseDisease ProgressionEnsureEpigenetic ProcessEquilibriumEventFamilyFosteringFunctional disorderFundingFutureGoalsGrantHeart DiseasesHeart failureHomeostasisIndividualInstitutesInvestmentsIsraelLearningLeftLifeLocationLouisianaMedical ResearchMedical centerMicroRNAsMinorityMolecularNational Heart, Lung, and Blood InstituteOralPathway interactionsRecruitment ActivityRequest for ProposalsResearchResearch PersonnelScheduleScienceScientistSecureSignal PathwaySiteStem Cell ResearchTherapeuticTimeTissue EngineeringTravelUncertaintyUnderrepresented MinorityUniversitiesUtahWorkabstractingcareercombatcostdesignexperiencefollow-upgene therapyheart metabolisminduced pluripotent stem celllecturesmedical specialtiesmeetingsmethionylmethioninenext generationnoveloutreachpostersprogramspublic health relevancesuccesssymposiumtherapeutic targettrend
中文摘要
描述(由申请者提供):这是美国心脏协会(AHA)2015年夏季基础心血管科学年会的新申请。在过去的10年里,这次会议得到了NHLBI的持续支持,这将是11周年纪念会议。来自NHLBI的支持帮助促进了一次会议,该会议已成为处理分子心血管生物学和疾病的“去”会议。它代表其赞助商,AHA的BCVS,这是世界领先的心血管科学家组织。这次会议最初始于20年前,当时理事会于1991年举行了一次分子心脏病学会议,然后有几次会议最初被誉为雪鸟会议,因为它是在犹他州的雪鸟夏季举行的。该会议在2002年成为一年一度的活动,自2004年以来,该会议一直被认为是AHA的永久性、经常性的科学会议,这也是R13资助开始的时候。近几年的会议增加了翻译话题,也增加了这次会议的基本内容,即基础分子心血管研究。这次会议一直吸引着诸如microRNA、心脏基因和细胞治疗、心脏开发以及最近的组织工程和iPS细胞等领域的领先研究人员。这次会议的出席人数每年都在攀升,2014年我们的出席人数达到了历史最高水平,超过600人。与往年一样,会议将于7月举行,今年将在拉斯维加斯举行两年后返回新奥尔良(2011年和2012年会议的地点)。会议将在洛杉矶新奥尔良的希尔顿新奥尔良河滨酒店举行。计划的议程代表了一次雄心勃勃、快节奏的会议,在4天内(2015年7月13日至16日)举行了14场会议,其中包括埃里克·奥尔森博士的主旨演讲。年轻的心血管科学家也将在每一次会议中通过特邀演讲得到突出强调,并将在为期3天的会议过程中展示海报。本次会议的组织者包括加州大学圣迭戈分校的Asa Gustafsson博士、贝丝以色列女执事医疗中心的Anthony Rosenzweig博士和路易斯安那州立大学的David J.Lefer博士。提案申请约占会议总预算的7%,正如我们在过去几年中所做的那样,这项申请的支持将用于心血管外展奖(少数族裔旅行奖)和青年调查员旅行奖。
英文摘要
DESCRIPTION (provided by applicant): This is a new application for the Annual Summer 2015 Symposium of the Basic Cardiovascular Sciences (BCVS) of the American Heart Association (AHA). This conference has had continuous support from the NHLBI for the last 10 years and this will be the 11th Anniversary meeting. Support from the NHLBI has helped foster a meeting that has become the "go to" conference dealing with molecular cardiovascular biology and disease. It represents its sponsor, the BCVS of the AHA, which is the world's leading organization of cardiovascular scientists. This conference started originally two decades ago as the Council held a Molecular Cardiology conference in 1991 and then had several meetings initially hailed as the Snowbird Conference as it was held during the summer at Snowbird, Utah. The meeting became an annual event in 2002 and since 2004 this conference has been recognized as a permanent, recurring scientific meeting of the AHA and which is when R13 funding also commenced. The conference in recent years has added translational topics as well as the "bread and butter" of this meeting, which is basic molecular cardiovascular research. The conference has always attracted the leading researchers in fields such as microRNA, cardiac gene and cell therapy, cardiac development and most recently, tissue engineering and iPS cells. The attendance of this conference has climbed every year and in 2014 we had an all-time high attendance of over 600. As in past years, the conference will be held in July and this year will return to New Orleans (the site of the 2011 and 2012 meetings) after two years in Las Vegas. The meeting will be held at the Hilton New Orleans Riverside, New Orleans, LA. The planned agenda represents an ambitious, fast-paced meeting with 14 sessions over 4 days (July 13-16, 2015) including the Keynote lecture by Dr. Eric Olson. Young cardiovascular scientists will be highlighted as well through invited talks in each session and Posters will be presented over the course of 3 days of the conference. Organizers of this meeting are Drs. Asa Gustafsson (UCSD), Anthony Rosenzweig (Beth Israel Deaconess Medical Center) and David J. Lefer (Louisiana State University). The proposal request constitutes approximately 7% of the total meeting budget and as we have done over the last several years, support from this application will be used toward Cardiovascular Outreach Awards (minority travel awards) and Young Investigator Travel Awards.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Full-scale GMP Production for a Pre-Clinical Systemic Delivered Mesenchymal Stem Cells Derived Extracellular Vesicles For Cardiovascular Disease
-
批准号:10721103
-
项目类别:
-
资助金额:$28.87万
-
财政年份:2023
-
负责人:Joshua M Hare
-
依托单位:
1/2 Allogeneic Human Mesenchymal Stem Cell (MSC) Injection in Patients with Hypoplastic Left Heart Syndrome: A Phase IIb Clinical Trial
-
批准号:10274833
-
项目类别:
-
资助金额:$117.83万
-
财政年份:2020
-
负责人:Joshua M Hare
-
依托单位:
1/2 Allogeneic Human Mesenchymal Stem Cell (MSC) Injection in Patients with Hypoplastic Left Heart Syndrome: A Phase IIb Clinical Trial
-
批准号:10295008
-
项目类别:
-
资助金额:$65.79万
-
财政年份:2020
-
负责人:Joshua M Hare
-
依托单位:
Production Assistance for Cellular Therapies (PACT)- Cell Processing Facilities Cell manufacturing and process development services for PCT0031-02: GMP Production of iPSC Line and Scale-up of Cardiac
-
批准号:10090766
-
项目类别:
-
资助金额:$101.72万
-
财政年份:2019
-
负责人:Joshua M Hare
-
依托单位:
A Phase 2b Clinical Trial to Study the Efficacy of Longeveron Mesenchymal Stem Cells (LMSCs) to Treat Aging Frailty
-
批准号:9922198
-
项目类别:
-
资助金额:$197.43万
-
财政年份:2018
-
负责人:Joshua M Hare
-
依托单位:
A Randomized, Blinded, Placebo-Controlled Clinical Trial to Evaluate Longeveron Mesenchymal Stem Cell (LMSC) Therapy for Treating The Metabolic Syndrome
-
批准号:9925908
-
项目类别:
-
资助金额:$46.55万
-
财政年份:2017
-
负责人:Joshua M Hare
-
依托单位:
A Randomized, Blinded, Placebo-Controlled Clinical Trial to Evaluate Longeveron Mesenchymal Stem Cell (LMSC) Therapy for Treating The Metabolic Syndrome
-
批准号:9348026
-
项目类别:
-
资助金额:$15.0万
-
财政年份:2017
-
负责人:Joshua M Hare
-
依托单位:
Nitric Oxide and sex differences in cardiac repair
-
批准号:9331951
-
项目类别:
-
资助金额:$40.61万
-
财政年份:2017
-
负责人:Joshua M Hare
-
依托单位:
Cell Based Therapy for Non-Ischemic Dilated Cardiomyopathy
-
批准号:8288406
-
项目类别:
-
资助金额:$71.55万
-
财政年份:2012
-
负责人:Joshua M Hare
-
依托单位:
Cell Based Therapy for Non-Ischemic Dilated Cardiomyopathy
-
批准号:8448599
-
项目类别:
-
资助金额:$65.07万
-
财政年份:2012
-
负责人:Joshua M Hare
-
依托单位:
Cell Based Therapy for Non-Ischemic Dilated Cardiomyopathy
-
批准号:8628873
-
项目类别:
-
资助金额:$66.46万
-
财政年份:2012
-
负责人:Joshua M Hare
-
依托单位:
Cardioprotective Effect of Growth Hormone Releasing Hormone
-
批准号:8065336
-
项目类别:
-
资助金额:$64.43万
-
财政年份:2011
-
负责人:Joshua M Hare
-
依托单位:
Cardioprotective Effect of Growth Hormone Releasing Hormone
-
批准号:8208055
-
项目类别:
-
资助金额:$62.55万
-
财政年份:2011
-
负责人:Joshua M Hare
-
依托单位:
Cardioprotective Effect of Growth Hormone Releasing Hormone
-
批准号:8411600
-
项目类别:
-
资助金额:$64.93万
-
财政年份:2011
-
负责人:Joshua M Hare
-
依托单位:
Stem Cells for Dilated Cardiomyopathy
-
批准号:8502552
-
项目类别:
-
资助金额:$62.02万
-
财政年份:2011
-
负责人:Joshua M Hare
-
依托单位:
Stem Cells for Dilated Cardiomyopathy
-
批准号:8880266
-
项目类别:
-
资助金额:$60.41万
-
财政年份:2011
-
负责人:Joshua M Hare
-
依托单位:
Stem Cells for Dilated Cardiomyopathy
-
批准号:8300026
-
项目类别:
-
资助金额:$65.13万
-
财政年份:2011
-
负责人:Joshua M Hare
-
依托单位:
Stem Cells for Dilated Cardiomyopathy
-
批准号:8205725
-
项目类别:
-
资助金额:$63.95万
-
财政年份:2011
-
负责人:Joshua M Hare
-
依托单位:
Cardioprotective Effect of Growth Hormone Releasing Hormone
-
批准号:8589378
-
项目类别:
-
资助金额:$64.84万
-
财政年份:2011
-
负责人:Joshua M Hare
-
依托单位:
Stem Cells for Dilated Cardiomyopathy
-
批准号:8680353
-
项目类别:
-
资助金额:$63.89万
-
财政年份:2011
-
负责人:Joshua M Hare
-
依托单位:
海外基金